Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today reported financial results for the ...
Key market opportunities for liraglutide and semaglutide include their growing role in diabetes and obesity treatment due to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback